Deciphering the anti-cancer efficacy of azadirachta indica and its role in re-expression of e-cadherin in breast cancer via snail and hdacs by Pradhan, Sonali
 
 
DECIPHERING THE ANTI-CANCER EFFICACY OF Azadirachta 
indica AND ITS ROLE IN RE-EXPRESSION OF E-CADHERIN IN 
BREAST CANCER VIA SNAIL AND HDACs 
 
 
Thesis submitted to 
NATIONAL INSTITUTE OF TECHNOLOGY, ROURKELA 
For partial fulfillment 
OF THE MASTER OF SCIENCE DEGREE IN LIFE SCIENCE 
 
 
 
Submitted by 
SONALI PRADHAN 
ROLL NO – 412LS2053 
 
 
 
Under the guidance of 
Dr. SAMIR KUMAR PATRA 
ASSOCIATE PROFESSOR AND HEAD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DEPARTMENT OF LIFE SCIENCE 
NATIONAL INSTITUTE OF TECHNOLOGY 
ROURKELA-769008, ODISHA 
2013-2014 
 
 
 
 
 
 
 
ACKNOWLEDGEMENT 
Writing this most difficult but non-taxing chapter is a soulful acknowledgement of 
gratitude towards people who stood to extend their helping hands in various ways during my 
project work. While few names are being mentioned many more are missing, I potray a deep 
seated gratitude to all these missing names.  
First and foremost, I express my reverence to “God almighty” for affording me enormous 
strength to overcome the adversities during the research project period.  
 I owe this unique opportunity to place on record my deep sense of gratitude & 
indebtedness to Dr. Samir Kumar Patra, Head of the Department Of Life Science, NIT 
ROURKELA for his scholastic guidance, prudent suggestions & persistent endeavour throughout 
the course of project. His affectionate personal attention has made my first exposure to research 
a memorable experience 
                My heartfelt gratefulness & special thanks to Ms. Sabnam Parbin, Senior Research 
Fellow for her immense help, valuable suggestions, constructive criticism and pain taking efforts 
in carrying out the experimental work successfully. 
               My ultimate respect and reverence goes to all my co-mates and PhD Scholars 
including, Ms. Arunima Shilpi, Ms. Moonmoon Deb, Mr. Dipta Sengupta , Ms. Swayamsiddha 
Kar, Mrs. Nibedita Pradhan and Mr. Sandip Rath for their self-less help, co-operative 
suggestions, moral support, care and affection during the work. 
   Lastly I express my abysmal adoration & heartfelt devotion to my beloved parents for 
their countless blessings, unmatchable love, affection & incessant inspiration that has given me 
strength to fight all odds & shaped my life, career till today. 
In the end I must record my special appreciation to my God who is always been a source 
of my strength, inspiration & achievements. 
 
 
 
 
 
                               
 
DECLARATION  
 
 
I hereby declare that this project report on, “DECIPHERING THE ANTI-CANCER 
EFFICACY OF Azadirachta indica AND ITS ROLE IN RE-EXPRESSION OF E-
CADHERIN IN BREAST CANCER VIA SNAIL AND HDACs”, is the result of the work 
carried out by me .Wherever contributions of others are involved, every effort is made to indicate 
this clearly, with due reference to the literature, and acknowledgement of collaborative research 
and discussions. The work was done under the guidance of Dr. Samir Kumar Patra, Associate 
Professor and Head, Department of Life Science, National Institute of Technology, Rourkela.  
 
 
 
 
 
 
 
  
 
 
Date:  
Place:                                                                                           (Sonali Pradhan) 
 
 
 
 
 
 
TABLE OF CONTENTS 
Sl. No. Title Pg. No 
1. Introduction 1-9 
2. Review of Literature 9-15 
3. Objectives 16 
4. Materials and Methods 17-23 
5. Results and Discussion 24-29 
6. Conclusion 29 
7. References 30-35 
 
 
 
 
 
 
 
LIST OF FIGURES 
Sl. No. Title of Figure Pg. No. 
1. 
Molecular structure of some bioactive components of neem 
(Azadirachta indica) 
2 
2. 
Epigenetic signaling tools 4 
3. 
Histone acetylation and deacetylation 6 
4. 
Role of Histone deacetylases (HDACs) in Cancer initiation & 
proliferation 7 
5. 
Graphical representation of standard GA calibration curve & 
total phenolic content in EENL & MENL 
24 
6. 
Graphical analysis of cell viability after EENL and MENL 
treatment 
25 
7. 
Fluorescence microscopic images representing condensed 
chromatin after EENL and MENL treatment in MDA MB 231 
breast cancer cells 
26 
8. 
Fluorescence microscopic images of comets showing DNA 
damage after EENL and MENL treatment and their graphical 
analysis 
26 
9. 
 Microscopic images showing changes in the migratory 
property of MDA MB 231 cells after EENL and MENL 
treatment 
27 
10. 
Representative images of semi-q-RT-PCR result depicting 
expression level of CDH1, Snail, HDAC-1, HDAC-2 and β-actin 
after EENL and MENL treatment 
28 
11. 
Graphical representation of expression levels of CDH1 & 
HDAC1 after EENL & MENL treatment 
29 
 
 
 
 
LIST OF TABLES 
Sl no. Title of Table Page No. 
1 Molecular structure of bioactive 
Components of Neem 
3 
2 Primers used for RT-PCR 22 
 
 
 
 
 
 
 
 
 
 
 
ABSTRACT 
Neem (Azadirachta indica), considered natural drug house, has been a source of 
numerous modern drugs in both developed and developing countries across globe. It provides 
with the active ingredients that act as a prophylaxis for the treatment of diverse ailments more 
specifically against cancer. The anti-cancer components of Neem comprising of azadirachtin, 
nimbolide, quercetin, limonin, glucopyranoside, azadirone, and deoxo nimbolide are targeted to 
the culprit enzymes accountable for tumor formation, subsequently combating cancer. Cancer, 
especially breast cancer has been responsible for the drastic mortality rate among all females. 
Cancer is characterized by genetic and epigenetic aberrations. These epigenetic aberrations are 
reversible thus accounting for the restoration of the functionality of tumor suppressor gene. In 
our study, we have carried out an effort towards checking the effect of neem extracts towards 
restoring the expression of tumor suppressor gene, E-cadherin (CDH1) via Snail and histone 
deacetylases (HDACs) in breast cancer cells MDA MB 231.Histone acetylation erasers, HDACs 
are the epigenetic manipulators playing a crucial role in silencing of tumor suppressor genes 
concerned with cancer initiation and progression. There are several HDAC inhibitors available 
but they have higher toxicity. Here, we have considered both the ethanolic and methanolic 
extracts of neem leaves (EENL and MENL), as they have been reported to be more effective 
than the aqueous extracts. The higher total phenolic content of EENL indicates its higher anti-
oxidant property, which accounts for its anti-cancer potential. Also the cytotoxicity, anti-
proliferative, apoptotic and anti-migratory potential of EENL are demonstrated to be more than 
that of MENL. Moreover, EENL restores more efficiently the expression of CDH1 and causes an 
enhanced transcript level of HDAC1 and HDAC2. Thus, it can be concluded that EENL may 
have HDAC inhibitory activity than MENL. Further research in this concern will shed more light 
on the HDAC inhibitory property of EENL and MENL on breast cancer cells. 
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1. INTRODUCTION 
India has a diverse culture of medicinal herbs and spices, which includes about more than 
2000 species. Plant & plant-derived compounds acted as a prophylaxis in the development of 
several anti-cancer agents. Plants provide the active ingredients including both primary & 
secondary metabolites such as-vincristine, vinblastine, flavonoids, terpenes, alkaloids, topotecan 
and irinotecan etc. These have been utilized by human beings for the treatment of diverse 
ailments for thousands of years [1]. There has been a great demand for herbal medicines in both 
developed and developing countries as a source of primary health care including ethno medicinal 
activities, high safety margins and lesser costs. Numbers of important modern drugs have been 
derived from plants inspite of the advent of modern or allopathic medicine, to be used by native 
people. Numbers of compounds used in mainstream medicine have been detected by researchers 
derived from "ethno medical" plant sources. There are numerous medicinal herbs that contribute 
a lot as anti-cancer agents. To name a few among them are, Azadirachta indica, Camellia 
sinensis, Catharanthus roseus, Withania somnifera, Boswellia serrata, Abrus precatorius, 
Albizzia lebbeck, Asparagus racemosus, Plumbago zeylanica and others. 
Azadirachta indica (Neem) presents greenhouse treasure cultivated in Indian 
subcontinent. It’s a member of the Meliaceae family. Neem because of its widespread domestic, 
therapeutic, agricultural &ethno medical applications is abbreviated as the ―sacred gift of nature‖ 
or ―natural drug house‖. All parts of neem including-leaves, barks, seed-oil, and twigs along with 
their purified products are widely used as anti-cancer agents. The phytochemicals being 
extracted from this plant include- nimbin, nimbidiol, azadirachtin, nimbidin and quercitin. These 
phytochemicals are of antiviral, antibacterial, antifungal, anti-malarial, antiseptic, anti-pyretic, 
anti-inflammatory, anti-oxidant, anti-ulcer and anticancer properties. The detailed study of 
bioactive components of Neem constitutes the following. 
1.1 Bioactive components of Neem (Azadirachta indica) 
 A major crude extract, Nimbidin isolated from the oil of seed kernels of neem exhibits 
several biological activities. Several tetranortriterpenes, including nimbin, nimbinin, nimbidinin, 
nimbolide and nimbidic acid have been isolated from this extract (Figure 1). It shows 
considerable dose reliant anti-inflammatory activity against carrageenin stimulated acute paw 
oedema in rats and formalin stimulated arthritis [2, 3]. Nimbidin has also been reported to exhibit 
anti-pyretic activity. Nimbolide, component of nimbidin inhibits the growth of Plasmodium 
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falciparum thus confirming anti-malarial activity[4] (Figure 2a). Also it exhibits anti-bacterial 
activity against S. aureus and S. coagulase while gedunin (in neem seed oil) has been reported to 
have anti-fungal and anti-malarial activities [5]. Azadirachtin a well oxygenated C-secomeliacins 
extracted from seed of neem possess strong anti-feedant action (Figure 2b). In addition, it also 
exhibits anti-malarial property. It displays inhibitory activity against the maturity of malarial 
parasites[6]. Mahmoodin (deoxygedunin), possess moderate antibacterial activity against few 
strains of human pathogenic bacteria. Condensed tannins comprising gallic acid, catechin, 
epicatechin, gallo-catechin, , and epigallo-catechin, among which epicatechin, gallic acid, and 
catechin inhibit the chemi-luminescence production via stimulated human poly-morphonuclear 
neutrophil (PMN) [7], thus indicative of restraining oxidative burst of PMN through 
inflammation. Three tricyclic di-terpenoids margolone, iso-margolonone and margolonone 
isolated from neem stem bark are act against Klebsiella, Staphylococcus and Serratia species. 
Polysaccharides extracted from neem display diverse biological effects. One of the 
polysaccharide isolated from neem bark shows inhibitory action against carrageenin-stimulated 
inflammation in mouse. Two polysaccharides GIa and GIb (water-soluble) extracted from the 
bark of Melia azadirachta, cause complete deterioration of the tumors, 24 h after subcutaneous 
inoculation of Sarcoma-180 cell whilst administered in mice at a daily dose of 50 mg/kg for four 
days [8]. GIIa and GIIIa (polysaccharides) isolated from M. azadirachta bark induced 
considerable anti-inflammatory effect on carrageenin-induced oedema in mice [8]. The detailed 
biological significance has been illustrated in Table 1. 
   
 
 
 
 
 
 
 
 
 
Figure 1. Molecular structure of some bioactive components of Neem (Azadirachta indica) 
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Table 1. Some bioactive components from Neem 
 
NEEM COMPOUND SOURCE BIOLOGICAL ACTIVITY 
Nimbidin Seed oil Anti-inflammatory, Anti-arthritic, Antipyretic, 
Hypoglycaemic, Anti-gastric ulcer, Spermicidal 
Antifungal, Antibacterial, Diuretic 
Sodium Nimbidate  Anti-inflammatory 
Nimbin Seed oil Spermicidal 
Nimbolide Seed oil Antibacterial 
Antimalarial 
Gedunin Seed oil Antifungal 
Antimalarial 
Azadirachtin Seed  Antimalarial 
Mahmoodin Seed oil Antibacterial 
Gallic acid, 
epicatechin,catechin 
 Anti-inflammatory 
immunomodulatory 
Margolone , margolonone and 
isomargolonone 
Bark Antibacterial 
Cyclic trisulphide and cyclic 
tetrasulphide 
Leaf Antifungal 
Polysaccharides  Anti-inflammatory 
Polysaccharides GIa , GIb Bark Antitumor 
Polysaccharides GIIa , GIIIa Bark Anti-inflammatory 
NB-II peptidoglycan Bark Immunomodulatory 
 
The anti-cancer components of Neem comprises of azadirachtin, nimbolide, quercetin, 
limonin, glucopyranoside, azadirone, and deoxonimbolide. These anticancer agents are targeted 
to the enzymes responsible for tumor formation subsequently combating cancer.  
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1.2 Epigenetics and cancer 
Epigenetics refers to the study of mitotically or meiotically heritable changes in gene 
function and/or phenotype without any changes in the underlying sequence of DNA. It involves 
no change in the underlying genetic program whilst; non-genetic factors cause expression of 
differential phenotypes in the organism's genes. Epigenetics has evolved as a rapidly emergent 
research area in the present scenario. Recent studies have revealed that epigenetics plays a vital 
role in cancer biology, mode of action of mobile elements, viral infections, gene therapy of 
somatic cell lines, transgenic technologies, genomic imprinting, developmental abnormalities, 
neurological disorders, and X-chromosome inactivation. The three major epigenetic signaling 
tools are: DNA methylation, RNAi associated silencing or activation and histone modification 
(Figure 2). 
 
 
 
 
 
 
Figure 2. Epigenetic signaling tools. 
 
1.2.1 DNA Methylation 
 
It is a DNA level modification. This refers simply the addition of a methyl (CH3) group 
to the 5’ carbon of cytosine pyrimidine ring or the 6’ nitrogen of the adenine purine ring. DNA 
methylation is one of the crucial regulators of transcription, and its role in inducing cancer has 
been a topic of significant interest in the past few years. Alterations in DNA methylation are 
familiar in a variety of tumors as well as in developmental abnormalities. Of all epigenetic 
modifications, hyper methylation, have been most extensively studied that causes repression of 
transcription at the promoter regions of tumors suppressor genes followed by gene silencing [9]. 
DNA methylation causes the silencing of genes whereas demethylation effects gene expression. 
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1.2.2. RNAi mediated gene silencing 
It occurs at RNA level. RNAi is an RNA-dependent gene silencing pathway under the 
control of RNA-induced silencing complex (RISC). The process is initiated by short ds (double 
stranded) RNA molecules in a cell's cytoplasm where they unite at the RISC complex.  
1.2.3. Histone Modifications 
Histone proteins, that package DNA into chromatin, are subject to several post 
translational modifications that ultimately affect gene regulation. These post-translational 
covalent modifications (PTMs) occur in the ε-N-terminal tails of histone proteins that regulate 
the transcriptional state of the genome via chromatin structure resulting in differential expression 
of genes. The various PTMs include- acetylation, methylation, sumoylation, phosphorylation, 
ADP ribosylation, citrullination, proline isomerisation and ubiquitination. These alter the 
interaction of DNA and nuclear proteins with histones. Histones are acetylated by histone acetyl 
transferases (HAT) & deacetylated by histone deacetyltransferases (HDACs). Histone 
modification plays an important role in gene transcription, and its role in carcinogenesis has been 
a topic of great interest in the past few years. 
1.3. Histone acetylation, deacetylation and gene regulation 
The Acetyl-Coenzyme A is the major source of the acetyl group in histone acetylation, 
and the acetyl group is transferred to Co-A in deacetylation. The negatively charged acetyl group 
neutralizes the positive charge on the histone & thus decreases the interaction of the histone with 
the phosphate group of DNA. This causes the transformation of folded structure into a relaxed 
structure (euchromatin) i.e., associated with greater levels of gene transcription (Figure 3). This 
can be reversed by HDAC activity that removes acetyl tags resulting in a more condensed 
structure of tightly packed DNA referred to as heterochromatin. Histone modifications have 
numerous utilities in varied biological pathways ranging from gene regulation, chromosome 
condensation and DNA repair. 
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Figure 3. Histone acetylation and deacetylation (Parbin et al, 2014) 
1.4  HDACs and cancer 
As we know cancer in short; a malignant tumor is a fatal disease resulting from 
regulatory mechanisms breakdown ultimately governing normal cell behavior. The propagation, 
delineation, and survival of individual cells in organisms are regulated carefully so as to meet the 
needs of organism as a whole. But this regulation is misplaced in cancer cells, which grow and 
divide in an unrestrained manner and subsequently spreading throughout the body through 
metastasis thus interfering with normal cellular behavior. It may occur at any age in any part of 
the body representing the largest cause of mortality in the world claiming over 6 millions [11]. 
Amongst all cancers, breast cancer is the chief cause of mortality in women both worldwide & 
Malaysia. 
Breast cancer contributes one of the most common malignancies in women estimated to 
be 182,460 new cases and reported for 40,480 deaths in 2008 in the United States (US)[12].  
Despite advent in molecular mechanisms of breast cancer and evolution in early detection and 
treatment, cancer cells either are intrinsically resistant or quickly acquire resistance against 
various cytotoxic chemotherapeutic drugs in 50% of cases[13].  Moreover, approximately 30% 
of all patients with early breast cancer stages will develop recurrent disease, which is principally 
metastatic and resistant to treatment [14, 15]. Currently, cancer metastasis and drug resistance, 
intrinsic or acquired, are chief obstacles in the successful treatment of breast cancer [16, 17]. 
Cancer is characterized by genetic and epigenetic aberrations. The epigenetic aberrations are 
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reversible thus the functionality of tumor suppressor gene can be restored. Epigenetic modulators 
play significant role in cancer. 
HDACs otherwise called histone acetylation erasers are one of such epigenetic 
manipulators which play a vital role in silencing of tumor suppressor genes concerned with 
cancer initiation and progression. Carcinogenesis includes the transition of normal cells into 
malignant cells which is characterized by uncontrolled cell proliferation, a lack of differentiation, 
including epithelial and hematopoietic differentiation, and the prevention of apoptosis. During 
cancer initiation, HDACs exert their silencing effects on cell-cycle checkpoint regulatory genes 
and genes associated with the differentiation process [10] (Figure 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.  Role of HDACs in Cancer initiation and proliferation (Parbin et al, 2014) 
1.4.1. Role of HDACs in cancer initiation and progression 
HDACs are responsible for uncontrolled cell proliferation by repressing the expression of 
specific cyclin dependent kinase (CDK) inhibitors-p21 and p27[18].Higher levels of HDAC2 
expression in Apc-deficient mouse adenomas are associated with loss of 15-
hydroxyprostaglandindehydrogenase (15-PGDH) expression. HDAC2 interacts with the 15-
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PGDH promoter, thereby causing its suppression. But, treatment with HDACi namely, 
Trichostatin-A (TSA),induces the expression of TGF- β RII and leads to formation of open 
chromatin conformation in lung cancer cells [19].HDACs are associated with loss of 
differentiation in cancer cells. Genes associated with differentiation elicits inappropriate cell 
proliferation on down-regulation. Pancreatic cancer cells that lack MUC2, upon treatment with 
TSA, were reported to inducing histone acetylation along with MUC2 mRNA and protein 
expression [20]. HDACs play crucial role in suppressing programmed cell death in various 
cancer cells. Noxa, member of the Bcl-2 family, up-regulated by p53 plays vital role in loss of 
apoptosis. It causes diminishing effects on apoptosis upon down-regulation. HDAC2 dictates 
epigenetic silencing of NOXA in pancreatic cancer cells [21]. Co-treatment with HDACi namely 
valproic acid (VPA) and TRAIL (TNF-α related apoptosis inducing ligand) causes enhanced 
apoptosis of pancreatic cancer cells [22]. HDACs are also involved in restraining the genes 
concerned with cancer progression. The two fundamental events associated with cancer 
progression are angiogenesis and metastasis. Angiogenesis refers to the development of new 
blood vessels from pre-existing ones. It comprises of two conditions i.e. normoxic and hypoxic. 
Hypoxic conditions in angiogenesis are interlinked with inducible expression of HDACs, 
includingHDAC1, 2, & 3[23, 24]. VEGF, platelet-derived growth factor produced by cells 
stimulates vasculogenesis and angiogenesis upon down-regulation. HDAC1overexpression leads 
to silencing of p53 and VHL but induces the hypoxia-responsive genes HIF-1 α and VEGF thus 
stimulating angiogenesis [23, 25]. A cell’s lack of ability to interact precisely with its external 
environment and its neighboring cells is the universal feature of metastasis. Metastasis is 
characterized by invasion, migration and then loss of adhesion. HDAC1 knockdown reduces 
cellular invasion by overexpression of cystatin, a peptidase inhibitor [26]. Also, HDACs inhibit 
CDH1 expressions that associate with hypoacetylated histones H3 and H4 at its promoter[27]. 
HDAC1 and HDAC2 function to suppress the CDH1 expression. On the contrary, treatment of 
pancreatic cells with HDACi restores the CDH1 with diminished EMT [28, 29].  
There are several HDACi known in the present scenario but some of them possess high 
toxicity and low specificity.  Henceforth, our study focuses on identification of anticancer 
property of Neem and its effect on HDAC and the tumor suppressor gene (E-cadherin). E-
cadherin (CDH1) is crucial mediator of cell-cell interactions, and playing a significant role in 
suppression of breast tumor. Its inactivation is mediated through instability at its chromosomal 
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locus and mutations as well as through epigenetic mechanisms namely hypermethylation of 
promoter and transcriptional repression. The transcription factor, Snail has been reported as a 
direct repressor of CDH1 expression during development and carcinogenesis by the recruitment 
of the Sin3A/Histone Deacetylase 1 (HDAC1)/HDAC2 Complex. Thus, upon targeting inhibitors 
to this complex will deactivate the functionality of the enzymatic complex which in turn will 
restore the expression of CDH1subsequently combating cancer. 
 
2. REVIEW OF LITERATURE 
Cancer, a multi-faceted ailment, is the main cause of morbidity globally, reporting for 7.6 
million deaths annually. Carcinogenesis is a multistep process involving three distinct stages 
namely- initiation, promotion, and proliferation [30]. Genetic susceptibility, environmental 
factors and epigenetic modifications play a key role in carcinogenesis. Exposure of human 
beings to chemical compounds in the environment is the most critical risk issue in malignant 
transformation[31]. The ideal traits of cancerous cells, i.e. growth signals self-sufficiency, 
insensitivity to growth suppressing signals, apoptosis evasion, unlimited replicative potential, 
persistent angiogenesis, tissue incursion, and metastasis cooperatively lead to the alteration of a 
typical cell to a malignant phenotype. The chronological buildup of aberrations that arises during 
carcinogenesis exhibits considerable prospects for experimental interferences to avert cancer 
initiation and treat pre-neoplastic conditions. Carcinoma of the breast, prostate and colon are 
highly prevalent maladies in the Western nations and reports for roughly half of the total cancer-
related mortalities among men and women [32]. Clinical therapies along with radiation, 
chemoprevention, immune-modulation and surgery in curing cancer have accomplished limited 
success. This is evident from the high mortality rates, thus indicating the urge for the 
development of new cancer management system. Chemo-prevention includes the use of dietary 
bio-factors, pharmacological, phytochemicals and even whole plant extracts to check, arrest, or 
reverse the cellular and molecular processes of carcinogenesis due to its manifold interference 
strategies [33]. The quest for compounds with few or no adverse effects that will block the 
invasion of cancer and protect against the adverse biological effects of chemotherapeutic agents 
as compared with the agents currently in use is henceforth of greatest relevance. Plant herbs and 
plant-derived drugs have therefore proven as the source of potent anti-cancer agents in 
conventional cultures worldwide and are becoming rapidly popular in current society [34]. 
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Natural phytochemicals derived from these herbs have shown noteworthy recognition in 
the management of several human ailments, including cancer [34, 35]. Much research has been 
oriented towards the plant extracts evaluation as prophylactic agents, presenting a great potential 
to repress the carcinogenic process. Simultaneously, the synergistic effects of the combination of 
plant metabolites and their multiple points of intervention offer higher efficacy during chemo-
preventive regimens [36]. The preventive machinery of tumor induction by natural 
phytochemicals range from the inhibition of genotoxic effects, increased antioxidants and anti-
inflammatory activity, inhibition of proteases and cell propagation, protection of intracellular 
communications to modulate apoptosis and signal transduction pathways. A number of new 
chemotherapeutic agents are being identified based on the ability to modulate one or more 
specific molecular events. The discovery of valuable herbs and elucidation of their underlying 
mechanisms could lead to the development of an alternative and corresponding method for 
cancer prevention and/or treatment. The Indian sub-continent has great botanical diversity and 
extensive usage of traditional medicine practice known as ayurveda; however, only a relatively 
small number of these plants have been subjected to accepted scientific evaluation for their 
potential anticancer effects [37]. 
The ability of neem extracts to remove cancerous phenotype was known long before to 
people in Asia, mostly in India. Researchers in India and abroad, during the last two decades, 
have put forwarded the opinion that the onset of cancerous phenotype resulted from mutagens 
and pro-carcinogens may be efficiently treated from extracts prepared from various parts of the 
neem tree. In vivo murine system, the chemotherapeutic property of dietary doses of aqueous 
neem leaf extract (ANLE) was observed against H-B-α-P(Benz-α-pyrene)-induced 
carcinogenesis in terms of 3H-B-α-P-DNA adduct formation. Their results showed that the 
metabolic activation of 3H-B-α-P is declined with subsequent decrease in the level of 3H-B-α-P-
DNA adduct in presence of ANLE [38]. In this investigation, the molecular and biochemical 
modulations seen at the initial stage of carcinogenesis reflects the chemo-therapeutic significance 
of A. indica.  
According to a study, conducted by Chaimuangraj et al., the neem leaf extract fed at 
doses of 20, 100, 250 mg/kg body weight drastically inhibit the azoxymethane-induced aberrant 
crypt foci (ACF) and also decrease the proliferating cell nuclear antigen (PCNA) labeling indices 
i.e. p < 0.0006 in the colon epithelium in rats. Several research groups have also verified the 
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preventive action of neem flowers against DMBA and BαP induced cancers [39-41]. These 
investigations showed that different parts of A. indica may be used in dietary form playing a 
crucial role in future drug discovery.  
O6-methylguanine-DNA methyltransferases (MGMT) is an enzyme that detoxifies O6-
alkylguanine, a potent mutagen and pro-carcinogen inducing agent, thus maintaining the 
genomic integrity. It has been demonstrated that the ethanolic and aqueous extracts of neem 
enhance the MGMT activity, thus resulting in time-dependent methylation of O6-methylguanine 
and consequently preventing its cytotoxic abrasions [42]. An enhanced elimination of these 
aberrations by increasing the MGMT activity is a beneficial chemotherapeutic strategy. 
Recently, it has been noted that the azadirachtin and nimbolide of neem extracts inhibit the 
development of DMBA-induced hamster buccal pouch (HBP) carcinoma in a dose-dependent 
manner via varied mechanisms, that include prevention of activation of pro-carcinogen, up-
regulation of antioxidant and carcinogen detoxifying enzymes and oxidative DNA damage [43]. 
Extracts from different parts of neem can also be used as tumor suppressors as proved by 
the researchers. Researchers from India and Japan have reported that polysaccharides and 
limonoids from neem leaves, bark, and seed oil declined the progression of tumors and cancers, 
reflecting its efficacy in lymphocytic leukemia. Additionally, researchers from Japan have shown 
that hot water extracts from neem bark posseses notable effectiveness against different types of 
cancers. Many of these extracts were equally effective or better than the coventional anticancer 
agents, especially in solid tumors. Ethanolic extracts (80%) from neem leaves, when 
administered at doses of 250–500 mg/ kg, decreased the average count of papilomas induced by 
BαP and DMBA in the 7-week-old Swiss albino mice model [44]. Similarly, Japanese 
researchers have demonstrated that nimbolide, a triterpenoid present in edible parts of A. indica, 
arrested the human colon carcinoma cells in G2/M and G0/G1 stages apparently through up-
regulation of p21. p21 is a well-known down-stream effector of the p53 gene, which is a very 
significant anticancer protein that monitors a number of genes involved in tumorigenesis. 
Similarly, Cyclin D2 and Chk2 have been found to be up-regulated, while the expression 
of cyclin A, cyclinE, Cdk2 and Rad17 were reduced when treated with nimbolide [45]. Kumar et 
al extensively carried out their research on U937, HL-60, THP1 and B16 cell lines and observed 
that nimbolide exerted anti-proliferative and apoptotic effects with reduction of bcl-2/bax ratio 
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and induction of Apaf-1 and caspase-3 expression. These experiments implied that the neem 
ingredients function through different molecular pathways to exert their anticancer effects [46].  
An experimental approach was followed by Subapriya et al. [47] in which they 
investigated the anticancer efficacy of ethanolic extracts of neem leaf (EENL) on DMBA-
induced carcinogenesis in buccal pouch of hamster basically emphasizing on their mode of 
regulation. Their investigations revealed engrossment of the PCNA (Proliferating cell nuclear 
antigen), mutant p53 and bcl2 genes. These genes are generally up regulated during DMBA-
induced cancer formation. EENL suppresses these genes as well as DMBA-induced cellular 
proliferation and differentiation. Bieberich et al, proposed that neem seed oil suppresses breast 
tumor formation in the ex vivo investigational models of female mice. They detected that 50 μl 
of neem seed oil inoculation at a dilution of 1:25 every week in MCF-7 cell line for roughly 50 
days reduced tumor affliction by 50%. These estimations present emphatic evidence assisting to 
improvise working strategies thus making use of anticancer efficacy of neem extracts for cancer 
treatment. 
2.1. Apoptotic activity of neem in cancer cells 
Apoptosis is a genetically driven process that leads to a series of biochemical events. 
These are characterized by blebbing, nuclear fragmentation, cell shrinkage, 
chromosomal DNA fragmentation, and chromatin condensation. It involves caspases, natural 
biochemical blades meant for surgery required to wipe out the unwanted, wayward, redundant 
and irreparable body cells without shedding even a single drop of blood and any material loss to 
the body as a whole. Treatment with neem extracts followed by cell viability assays and DNA 
fragmentation, has reported to induce apoptosis in a dose-dependent manner in prostate cancer 
cells (PC-3) [46].These observations exhibit that there is suppression in the bcl-2 protein 
expression, a strong pro-survival factor in cancer cells and simultaneously enhanced the pro-
apoptotic Bax protein level of expression. Neem extract could thus be a potentially effective 
treatment against prostate cancer. Working on the choriocarcinoma cells, Kumar et al[48] have 
shown that nimbolide, which is an active anticancer active component of the neem leaf and 
flowers, induces apoptosis through engagement of the mitochondrial pathway. This pathway is 
based on the fact that nimbolide mediates up-regulation of Apaf1 andcaspase3 and leads to 
decrease in the bcl2/bax ratio. Nimbolide has been observed to disrupt cell cycle check points 
(G2/M, G0/G1 and G/S) in correlation to induction of apoptosis on treatment with U937, HL-60, 
13 
 
THP1 and B16 cell lines [49]. The molecular correlation that exists between cell cycle disruption 
and apoptosis has not been clearly shown by them in these cells lines. Often, cell cycle disruption 
followed by arrest of cells at the cell cycle check points is attributed to immunity against 
apoptosis. 
The anti-proliferative activity of ethanolic neem leaves extract (EENL) has been well 
demonstrated. EENL alone or in combination with cisplatin targets cell proliferation by cell 
viability assay on human breast (MCF-7) and cervical (HeLa) cancer cells. Nuclear 
morphological examination and cell cycle investigation were performed to establish the mode of 
cell death. Further, in order to identify its molecular targets, the expression of genes concerned 
with apoptosis, cell cycle progression, and drug metabolism was analyzed by RT-PCR. 
Treatment of MCF-7, HeLa, and normal cells with EENL differentially suppressed the growth of 
cancer cells in a dose and time dependent manner through apoptosis. Furthermore, lower dose 
combinations of EENL with cisplatin resulted in synergistic growth inhibition of these cells in 
comparison to the individual drugs. EENL modulated the expression of bax, cyclinD1, and 
cytochrome P450 mono-oxygenases (CYP 1A1 and CYP 1A2) drastically in a time-dependent 
manner in these cells. These results highlight the chemo-preventive ability of neem alone or in 
combination with chemotherapeutic treatment to minimize the cytotoxic effects on normal cells, 
while strengthening their efficacy at lower doses [50].Thus, neem may be a regarded as a 
forthcoming therapeutic agent to combat gynecological cancers. 
 Multiple active components are present in Azadirachta indica possessing potent anti-
inflammatory and anticancer properties. This study investigates the novel targets of the 
anticancer activity of ethanol extract of neem leaves (EENL) in vitro and evaluates the in vivo 
efficacy in the prostate cancer forms. Analysis of the components in the EENL by mass 
spectrometry suggests the occurrence of 2’, 3’-dehydrosalannol, 6-desacetyl nimbinene, and 
nimolinone. C4-2B and PC-3M-luc2 prostate cancer cell lines upon treatment with EENL show 
inhibitory activity on cell propagation. Genome-wide expression analysis, utilizing oligo-
nucleotide microarrays, unveiled the differential gene expression with EENL treatment in 
prostate cancer cells. Their functional investigation revealed that most of the up-regulated genes 
were associated with drug metabolism and cell death, and the down-regulated genes were 
associated through cellular cycle, replication of DNA, recombination, and repair functions. 
Quantitative PCR analysis confirmed significant up-regulation of 40 genes and immunoblotting 
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disclosed increase in the protein expression levels of HMOX1, AKR1C2, AKR1C3, and 
AKR1B10. The growth of C4-2B and PC-3M-luc2 prostate cancer xenografts in nude mice was 
inhibited upon EENL treatment. Basically tumor growth suppression is associated with the 
formation of hyalinized fibrous tumor tissue and the induction of cell death by apoptosis. These 
results revealed that EENL containing natural bioactive compounds retain potent anticancer 
property and the regulation of multiple cellular pathways could exert pleiotropic effects in 
prevention and cure of prostate cancer[51]. 
It has been well documented in a study that ethanolic neem leaf extract displayed down 
regulation on c-Myc oncogene expression in 4T1 breast cancer BALB/c mice. c-Myc oncogene 
expression was down regulated in in- situ RT-PCR when stimulated by 500 mg/kg of ethanolic 
neem leaf extract[11]. This suggested that in physiological circumstances, neem retains the 
ability to minimize cellular propagation in response to the cancer in mice [52]. For tumor 
induction, c-Myc not only requires to promote cell propagation, but also concurrently restrains 
its inclination towards cellular death, in order to raise cell numbers to form a tumor mass [53]. 
The suppressed expression of c-Myc in neem treated cancer mice has not only shown a tendency 
towards inhibiting the cancerous cells proliferation but also to induce apoptosis against 4T1 
cancer cells. A variety of chemotherapeutic drugs can initiate apoptosis in tumor cells, leading to 
the degeneration of a cancerous tumor.   
Additionally another investigation has demonstrated that consumption of 5% of aqueous 
extract of neem leaves resulted in increase of antioxidant enzymes to a level of absolute 
inhibition of chemically induced hepato-carcinogenesis in rats. These studies revealed that neem 
may contribute its greatest effect against the 4T1 breast cancer model not only via apoptosis 
induction but also by its antioxidant bioactivity. The overall results exhibits that the ethanolic 
neem leaf extract has a significant effect against breast cancer in the 4T1 mouse model. But 
detailed study is needed to understand the mechanism of neem leaf extract on oncogene 
expression [11]. 
In the present scenario, no such research work has been oriented towards synergistic 
activity of both Neem and HDACS to combat cancer. But, interrelationship between HDACS 
and cancer has been well demonstrated as described below. 
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2.2 .  HDACs and Metastasis 
HDACs upon interaction with cystatin and e-cadherin effect invasion, migration and then 
loss of adhesion. HDAC1 knockdown reduces cellular invasion by overexpressing cystatin, a 
peptidase inhibitor [26]. Also, HDACs inhibit CDH1 expressions that associate with 
hypoacetylated histones H3 and H4 at its promoter [27]. CDH1 expression is often lost in 
prostate cancer cells in due to the high expressivity of HDACs, especially HDAC1, a key 
repressive enzyme for this silencing [54]. Silencing of CDH1is carried out by HDAC1 and 
HDAC2 during the metastatic process of pancreatic cancer cells. The underlying mechanism 
involves recruitment of transcriptional silencers, ZEB and Snail to the CDH1 promoter which, in 
turn recruit HDAC1 and HDAC2. These HDAC1 and 2 in turn functions to suppress the CDH1 
expression. On the contrary, treatment of pancreatic cells with HDACi restores the CDH1 with 
diminished EMT [28, 29]. HDAC1 and HDAC2 are also essential components of the co-
repressor complex— EZH2/HDAC1/2/Snail—concerned with the silencing of CDH1 causing 
EMT in nasopharyngeal cancer [55]. 
 
2.3.  Synergistic effect of Snail & Slug on E-cadherin  
Conversion of premature stage tumors into invasive malignancies constitutes one of the 
hallmarks in tumorigenesis [56]. It is basically associated with activation of the embryonic EMT 
program [57-59]. Thus, the early detection of EMT development or attenuation of the EMT 
phenotype in cancer cells may boost classical chemotherapy treatment and improve the clinical 
management of cancer. E-cadherin (CDH1) expression emerges as a critical step driving EMT in 
various human cancers, including invasive breast cancer [60, 61]. Several mechanisms have been 
proposed for transcriptional repression during EMT, as well as promoter CpG island hyper-
methylation [62] and direct inhibition by transcriptional repressors such as Snail [63]. 
Transcription factor, Snail requires histone deacetylase (HDAC) activity to repress CDH1 
promoter.  Overexpression of Snail is correlated with deacetylation of histones H3 and H4 at the 
CDH1 promoter.  It is also involved in epithelial to mesenchymal transitions(EMTs) where they 
are overexpressed in epithelial cell lines as well as in embryonic development thus acting as 
inducer of invasive breast cancer [64]. 
 
 
16 
 
 
3. OBJECTIVES 
 
a. To study the anti-proliferative effect of ethanolic and methanolic extracts of Azadirachta 
indica leaves on MDA MB 231 breast cancer cells. 
b. Deciphering the apoptotic potential of ethanolic and methanolic extracts of Azadirachta 
indica leaves on MDA MB 231 breast cancer cells. 
c. To study the anti-migratory effect of ethanolic and methanolic extracts of Azadirachta 
indica leaves on MDA MB 231 breast cancer cells 
d. To investigate the role of ethanolic and methanolic extracts of Azadirachta indica leaves 
on expression of tumor suppressor gene (E-cadherin), transcription factor (SNAIL) and 
epigenetic manipulators (HDAC1, HDAC2) on MDA MB 231 breast cancer cells with 
establishment of correlation among them. 
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4. MATERIALS AND METHODS 
4.1. Preparation of Plant extracts (EENL, MENL): 
 Neem (Azadirachta indica) leaves were collected from the National Institute of 
Technology (NIT), Rourkela campus. The leaves were washed with distilled water and air dried. 
Then the leaf extracts were prepared according to Othman et al, 2011. The leaves were ground 
using a grinder to obtain the fine powdered form. A total of 50 g of powdered neem leaf was 
transferred into a borosilicate glass bottle to which 100 ml of 80% ethanol was added. The 
mixture was mixed and kept overnight at room temperature. The other day, the mixture was 
filtered into a beaker while the residue was left in the borosilicate glass bottle. Another 100 ml of 
80% ethanol was then poured into the borosilicate glass bottle to soak the remaining residue, 
which was then kept overnight at room temperature. These steps were then repeated for the next 
three consecutive days. Ethanolic extract of neem leaves (EENL) was evaporated using a rotary 
evaporator (RV 10 Basic IKA Rotary Evaporator) at 60˚C. Same procedure was repeated for 
methanolic extracts of neem leaves (MENL) preparation, but in this case 50gm of powdered 
leaves was extracted in100 ml of absolute methanol.  After this the extracts were oven-dried for 
an additional 48 hours and then crude form stored at -20˚C.An aliquot of 200 mg of this dried 
extracts were dissolved in 500μL of di-methyl sulfoxide (DMSO) to prepare a stock of 
concentration 400 μg/μL. Secondary stock solutions of 40μg/μL were prepared by diluting the 
primary stock with ethanol and methanol for ethanolic and methanolic extract, respectively. The 
suspensions were then filtered with a 0.22µm filter and stored at -20˚C. The final concentration 
of DMSO never exceeded 0.01% in the culture medium. 
4.2. Estimation of total phenolic content: 
The phenolic content of plant extracts was determined from a gallic acid (GA) calibration 
curve. To develop the standard curve, 0.5 mL aliquots of 12.5, 25, 50, 100, 200, and 400 μg/mL 
concentrations of methanolic gallic acid solutions were prepared from a stock of 400 mg/ml 
solution and EENL and MENL were diluted to the concentration 200 µg/mL. Then to each 
concentration of solution, 2.5 ml Folin’s reagent (diluted 1:9) and 2.5 ml (7.5g/100 mL) sodium 
carbonate were added. All determinations were performed in duplicate. The reaction mixture was 
incubated at 25
0
C for 30 min. Then phenolic contents were determined at 765 nm against reagent 
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blank by UV Spectrophotometer (PerkinElmer). Total phenols were determined as gallic acid 
equivalents (GAE)(mg GAE/g extract) by the following formula:  
C = c x V / m  
where, 
            C - total content of phenolic compounds, mg/g plant extract, in GAE 
            c - the concentration of gallic acid established from the calibration curve, mg/mL 
 V - the volume of extract, mL; 
 m - the weight of pure plant methanolic/ethanolic extract, g. 
4.3. Cell Line and Cell Culture: 
MDA MB 231, a breast cancer cell line was procured from National Center for Cellular 
Sciences (NCCS), Pune. The cells are known to be of epithelial breast adeno-carcinoma origin 
and are triple negative. All culture works were carried out under strict aseptic conditions. Cells 
were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal 
bovine serum and 100 units/ml penicillin-streptomycin sulfate (Invitrogen) in a humidified 
incubator supplied with 5% CO2 at 37˚C. 
4.4. Cell viability assay: 
This assay was done to determine the sub-lethal concentrations (IC50) of extracts and 
proliferative activity of the cells in presence of extracts. MDAMB 231 (80 % confluent) cells 
were seeded into 96 well-plate at a density of 3×10
3
 cells/well. After 24 h, the cells were treated 
with neem extracts i.e ethanolic and methanolic extract of neem leaves (EENL, MENL) at  7 
different concentrations (10-100μg/mL for EENL and 10-700μg/mL) and incubated for 24 h and 
48 h. In parallel the cells with the solvent control was also treated to assess its effect on cells. 
After completion of treatment duration, to detect the cell viability MTT working solution was 
prepared by diluting the stock solution (stock 5mg/ml PBS, PH 7.2) in growth medium without 
FBS to the final concentration of 0.8mg/ml. 100 μl of MTT working solution was added to each 
well and incubated for 4 hours in CO2 incubator. After incubation, the media was removed 
carefully without disturbing formazan precipitate and dissolved in 100 μl of 100% DMSO. An 
incubation of 15 minutes was carried out in dark and the colorimetric estimation of formazan 
product was performed at 570nm in a microplate reader (Perkin Elmer). The experiment was 
repeated thrice and the data (mean ± S.D) were plotted against drug concentration and non- 
linear regression curve fitting was performed. 
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4.5. Clonogenic assay: 
MDA-MB-231 cells were plated at a low density (300 cells/well) in a 6 well plate, allowed to 
attach for 24 hours prior to treating with the extracts. Then cells were treated with MENL and 
EENL at their respective IC50 values. Cells were grown until distinct colonies were visible in 
untreated controls. Then they were fixed and stained with a mixture of 6.0% glutaraldehyde and 
0.5% crystal violet, air dried, photographed and evaluated for colony estimation. 
4.6 Analysis of chromatin condensation by Hoechst 33342 stain: 
For chromatin condensation assay, MDA-MB-231 breast cancer cells (10
4
cells/well) 
were seeded in 6 well culture plates and allowed to grow for one day. Then cells were treated 
with EENL and MENL at their respective IC50 values. After 24 hours of drug treatment, cells 
were stained with Hoechst 33342 (1 mg/ml) and incubated for 10 min at 37°C and images were 
taken under UV filter using Epi-fluorescent Microscope (Olympus IX71) at 400 X 
magnification. Condensed nucleus was counted against total number of nucleus in the field, and 
the percentages of apoptotic nuclei were analyzed. 
4.7 Measurement of DNA Damage by Comet Assay 
Comet assays were performed under alkaline conditions to determine the amount of 
double-strand DNA breaks. Two water baths were equilibrated at 40 °C and 100 °C respectively. 
Then 1% low-gelling-temperature agarose was prepared by mixing powdered agarose with 
distilled water in a glass bottle. The bottle was placed in the 100 °C water bath for several 
minutes and was transferred into a 40 °C water bath. Agarose-precoated slides were prepared by 
dipping the slides into molten 1% agarose and wiping one side clean. Agarose was allowed to 
air-dry to a thin film. Slides were prepared ahead of time and stored with desiccant. 
MDA-MB-231 was subjected to treatment with MENL and EENL at their respective IC50 
values for 24 h. Then cells were harvested and added to preheated (37°C) low-melting point 
agarose. The solution was pipetted onto slides precoated with 1% agarose. The slides were 
allowed to lyse overnight  at 4°C in alkaline lysis solution (1.2 M NaCl, 100 mM Na2EDTA, 
0.1% sodium lauryl sarcosinate, 0.26 M NaOH, pH > 13) prior to immersion in alkaline 
electrophoresis solution (0.03 M NaOH, 2 mM Na2EDTA, pH ∼12.3). After 30 min, slides were 
placed into a horizontal electrophoresis chamber samples for 25 min (0.6 V/cm). The slides were 
washed with deionized H2O to remove the alkaline buffer, stained with propidium iodide (10 
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μg/ml stock) and incubate for 20 min. The slides were then washed with water and examined by 
Epi-fluorescent Microscope (Olympus IX71).  
4.8. Cell migration assay (Scratch assay): 
MDA-MB-231 were seeded to6 well plate to create a confluent monolayer and incubated 
properly for approximately 6 hours at 37°C, allowing cells to adhere and spread on the substrate 
completely. The required number of cells for a confluent monolayer depends on both the 
particular cell type and the size of dishes and need to be adjusted appropriately. The cell 
monolayer was scraped in a straight line to create a scratch with a p200 pipette tip. 
The debris was removed and the edge of the scratch was smoothed by washing the cells 
once with 1 ml of 1XPBS, pH7.2 and then replaced with 2 ml of DMEM containing MENL and 
EENL at their respective IC50 values. To obtain the same field during the image acquisition 
markings were created to be used as reference points close to the scratch. The first image of the 
scratch was taken and referred as 0 hour. After the wound in the control was healed up the 
photographs were taken under a phase-contrast microscope. 
4.9. Total Cellular RNA isolation  
The total cellular RNA was extracted using TRI reagent (Sigma), following the 
manufacturer's instructions. MDAMB 231 cells were homogenized using TRI reagent i.e. 1 ml of 
the TRI Reagent per 10 cm
2
 of glass culture plate surface area. After addition of the reagent, the 
cell lysate was passed several times through a pipette to form a homogenous lysate. Phase 
separation was done by allowing the samples to stand for 5 minutes at room temperature 
followed by addition of 0.2 ml of chloroform per ml of TRI reagent. Samples were covered and 
shaken vigorously for 15 seconds, allowing standing for 10 minutes at room temperature. The 
resulting mixture was centrifuged at 12,000g for 15 minutes at 4°C. Centrifugation separates the 
mixture into 3 phases: a red organic phase (containing protein), an interphase (containing DNA), 
and a colorless upper aqueous phase (containing RNA). The aqueous phase was transferred into 
a fresh tube and 0.5 ml of isopropanol was added per ml of TRI Reagent & mixed. The sample 
was allowed to stand for 5–10 minutes at room temperature and centrifuged at 12,000 g for 10 
minutes at 2–8 °C. The RNA precipitate formed a pellet on the side and bottom of the tube. The 
supernatant was removed and RNA pellets were washed by adding a minimum of 1 ml of 75% 
ethanol per 1 ml of TRI Reagent. The sample was vortexed and then centrifuged at 7,500 g for 5 
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minutes at 4 °C. The RNA pellets were dried briefly for 5–10 minutes by air drying. An 
appropriate volume of nuclease free water was added and mixed by repeated tapping at 25 °C for 
10–15 minutes. 
4.10. Quantification of total cellular RNA 
Final preparation of RNA was analyzed using a nano-drop UV spectrophotometric 
analyzer. The standard preparation of RNA is expected to have a 260/280 ratio of 1.8-2.0 and a 
260/230 ratio of <1.65, which indicates the preparation to be free from proteins and oligo-
peptides contamination. 
4.11. cDNA preparation 
In a 1.5 ml tube, 2 μg of template RNA was taken and the volume was adjusted to 11μl 
with nuclease free water. To it 1 μl of oligo-dT primer was added to make a total volume of 12 
μl. The tube with the contents was mixed by centrifugation and incubated at 65°C for 5 minutes. 
The tube was then snap cooled on ice and given a short spin. After that 4 μl of Reverse 
Transcriptase buffer (5X ) ,1 μl of Ribolock RI, 1 μl of Reverse Transcriptase, and 2 μl of 10mM 
dNTP mix  was added to make a total volume of the reaction mixture 20 μl .The tube was then 
snap spinned for few minutes. The PCR was carried and the DNA was amplified under the 
following conditions- i.e. 42°C for 60 minutes and terminated at 70°C for 5 minutes. The 
amplified cDNA was stored at -20°C for further processing. The synthesized cDNA was 
evaluated by performing PCR over one of the house keeping genes such as β-actin. 
β-actin mRNA expression as internal control 
The amount of cDNA of different samples was so adjusted to have the expression of 
housekeeping gene (β-actin) similar in both control and treated samples.  
4.12. Gradient PCR  
The PCR primers were chemically manufactured and procured from Sigma.A gradient 
PCR was done to optimize the annealing temperature of each set of primers. We used five sets 
of primers to amplify E-cadherin (CDH1), Snail, HDAC-1, HDAC-2 and β-actin genes having 
sequence as detailed in Table no.2.The annealing temperature for each set of primers was 
optimized from 50˚C to 58˚C in order to obtain the most suitable temperature for the primers to 
be annealed on the target sequence. The PCR were carried out using standard protocols in a 
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thermocycler (Bio-Rad) and the DNA was amplified under the following conditions: 95 °C for 5 
min, 35 cycles of 95 °C for 30 s, 50˚C to 58˚C for 30 s, and 72 °C for 30 s, and the final 
extension of 72 °C for 5 min. The PCR products for each sample were electrophoresed on a 
1.5% agarose gel to determine the optimum annealing temperature.  
Table 2. Primers used for RT-PCR Analysis 
SL. 
NO. 
PRIMER NAME PRIMER SEQUENCE 
AMPLICON 
SIZE (in bp) 
1 E-cadherin Forward primer 5’-CGAGAGCTACACGTTCACGG-3’ 119 
E-cadherin Reverse primer 5’-GGGTGTCGAGGGAAAAATAGG-3’ 
2 SnailForward primer 5’-TCTAGGCCCTGGCTGCTACAA-3’ 131 
Snail Reverse primer 5’-ACATCTGAGTGGGTCTGGAGGTG-3’ 
3 HDAC1Forward primer 5’-GGAAATCTATCGCCCTCACA-3’ 168 
HDAC1 Reverse primer 5’-AACAGGCCATCGAATACTGG-3’ 
4 HDAC2Forward primer 5’-ATAAAGCCACTGCCGAAGAA-3’ 245 
HDAC2 Reverse primer 5’-TCCTCCAGCCCAATTAACAG-3’ 
5 β- actinForward primer 5’-TCTACAATGAGCTGCGTGTG-3’ 250 
β- actin Reverse primer 5’-TCTCCTTCTGCATCCTGTC-3’ 
 
4.13. Gene Expression Analysis of CDH1, Snail, HDAC-1, HDAC-2 by Semi-quantitative 
reverse-transcription PCR (Semi-q-RT-PCR) 
MDA-MB-231 cells were treated with sub lethal dosages of EENL &MENLfor24 hours. 
Total cellular RNA was extracted from treated samples and untreated control with TriReagent 
(Sigma) according to the manufacturer’s instructions. cDNA was prepared using Thermo 
Scientific Revert Aid First Strand cDNA Synthesis Kit. cDNA from different treatment groups 
were used to analyze the expression of CDH1, Snail, HDAC1 and HDAC2 gene along with β-
Actin as a house keeping gene. 
PCR conditions: 
The PCR sample mixtures, in a 20 μl volume, contained 15.4μl of nuclease free water, 2 
μl of 10X PCR buffer (Thermo Scientific), 0.2 mM of dNTP (Thermo Scientific), 0.2 μM each 
of the forward and reverse primers of CDH1, Snail, HDAC1, HDAC2, β-actin (Sigma) and 0.2 
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μl Taq DNA-polymerase (0.05U/μl, Pure gene) and optimized amount of each cDNA sample (in 
μl) was added. PCR amplifications of CDH1, Snail, HDAC1, HDAC2, β-actin were performed 
in a thermal cycler by initial denaturation at 95 °C for 5 min, 35 cycles of 95 °C for 30 s, 53˚C 
for 30 s, and 72 °C for 30 s, and the final extension of 72 °C for 5 min. 
4.14.  Agarose Gel Electrophoresis of the PCR products: 
The generated PCR products were analyzed by electrophoresis on 1.5% agarose gel. 
Agarose gel was prepared with 1X TAE (Tris Acetate EDTA, Sigma) buffer. Before casting 
1.5μl of ethidium bromide was added to the gel. 10 μl of sample (PCR product) was loaded to 
each well along with 2μl of 5 X loading dye. 1μl of ladder was loaded. The gel was run in TAE 
buffer at 80 volt for 35 minutes. 
4.15. Analysis of the Relative Expression level of Maspin and HDAC-1 by quantitative 
reverse-transcription PCR (q-RT-PCR) 
qRT-PCR was performed using SYBR® Green JumpStart™ TaqReadyMix in the 
Realplex4 Eppendorf system for CDH1 and HDAC1 gene. The mRNA level was normalized to 
β-Actin. The primer sequences for real time PCR are same as that of semi-q-RT-PCR and are 
given in Table 2.  
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5. RESULTS AND DISCUSSION 
5.1. Estimation of total phenolic content 
Total phenolic content of neem leaf extracts (EENL and METL) was determined using 
Folin-Ciocalteu assay (Khatoon et al., 2013). Samples comprising phenolic compounds are 
reduced by Folin-Ciocalteu reagent thereby generating a blue-coloured complex. The greater 
amount of phenolic complexes causes more potent free radical scavenging effects. Oxidation 
produces free radicals in food, drugs and often in living systems also (Pourmorad et al, 2006). 
These free radicals in turn cause various disorders in humans. Due to degradation of natural 
antioxidants in our immune system, consuming antioxidants that serve as free radical scavengers 
is indispensable. Antioxidant property of plants is most probably due to their phenolic 
compounds (Cook and Samman, 1996). Azadirachtaindica consists of flavonoids, a group of 
polyphenoliccomplexes associated with free radical scavenging activity. Phytochemicals with 
phenolic complexes have anticancer properties. Both mono and polyphenolic complexes in plant 
extracts suppress or inhibit the initiation, progression and invasion of cancers in cells in vitro 
(Wahle et al, 2010). Phenolic complexes can contribute to our body’s immune system by 
recognizing and destroying cancerous cells as well as suppressing angiogenesis required for 
tumor growth. They are also associated with attenuating adhesiveness, invasiveness and 
propagation of cancer cells thereby weakening their metastatic potential. The higher phenol 
content of EENL than MENL indicates its higher anti-oxidant potential, which in turn can be 
correlated with its anti-cancer potential. The higher anti-cancer property of EENL has been 
further evaluated by investigating its anti-proliferative, apoptotic and anti-migratory activity on 
MDA MB 231 breast cancer cells (Figure 5). 
 
 
 
 
 
Figure 5. Standard GA calibration curve & total phenolic content in EENL & MENL. 
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5.2. Determination of  cytotoxic effect and IC50 value of EENL and MENL by cell viability 
assay 
Cell viability of MDA MB -231 was determined after EENL and MENL treatment by MTT 
Assay. The IC50 values for both the extracts were calculated. Both the EENL and MENL 
treatment showed decrease in cell viability but EENL treatment showed higher decrease in cell 
viability indicating more cytotoxicity towards breast cancer cells. 
We determined the sub-lethal concentration of different extracts (EENL and MENL) by 
MTT assay, which was taken as standardized concentration for further treatment. The optimized 
IC50 values of EENL & MENL are found to be 35 µg/ml and 500 µg/ml for 24 h MDA-MB-231 
cells (Figure 6). 
 
Figure 6.Graphical analysis of cell viability after EENL and MENL treatment 
5.3. Detection of apoptosis induced by EENL and MENL by Chromatin condensation 
assay 
The cell death inducing ability of neem leaf extracts is determined by chromatin 
condensation assay. This is indicated by formation of highly condensed and fragmented 
apoptotic bodies. Here, we found that the number of condensed nuclei in EENL treatment is 
comparatively more than that of MENL in MDA MB 231 breast cancer cells. The untreated 
controls show no condensed or fragmented nuclei (Figure 7).  
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Figure 7. Fluorescence microscopic images representing condensed chromatin after EENL 
and MENL treatment in MDA MB 231 breast cancer cells. 
5.4. Measurement of DNA damage induced by EENL and MENL by Comet assay 
 
Comet assay denotes the extent of DNA damage due to apoptosis on application of any 
insults to the cells. The tail moment denotes the apoptosis inducing ability of extracts. The tail 
moment of comet in case of EENL treatment is higher than MENL (Figure 8). The characteristic 
comet tail length suggested the amount of DNA damaged.  
 
 
Figure 8. Fluorescence microscopic images of comets showing DNA damage after EENL 
and MENL treatment and their histogram analysis. 
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5.5. Determination of anti-migratory activity of EENL and MENL on MDA MB 231 cells 
by Scratch assay  
 
To determine the migratory property of the MDA MB-231 cells after EENL and MENL 
treatment for 24 h, the scratch assay was performed. While in control, the cancer cells migrate 
and close the gap in 24 h, in treatment groups very less number of cells migrate towards the gap. 
This indicates the anti-migratory property of neem extracts. Moreover, the wound healing ability 
of EENL is found to be least among all. The results showed that there was more migration of 
cells towards the scratched area in MENL treated cells as compared to the EENL treated cells in 
comparison with the untreated plates taken as control (Figure 9). This clearly demonstrates the 
efficient anti-migratory property of EENL on breast cancer cells. 
 
 
Figure 9. Microscopic images showing changes in the migratory property of MDA MB-231 
cells after EENL and MENL treatment. 
 
5.6. Gene Expression Analysis of CDH1, Snail, HDAC-1, HDAC-2 by Semi-quantitative 
reverse-transcription PCR (Semi-q-RT-PCR) 
 
Semi-q-RT-PCR data confirmed that the transcript level of CDH1is increased in MDA-MB 
231breast cancer cells after treatment with EENL and MENL. CDH1 is a tumor suppressor gene, 
which has been reported to have low expression in breast cancer cells (Burstin). Here in our 
study we also found the lower expression of CDH1 at transcription level. On treatment with 
EENL and MENL, the CDH1 is demonstrated to be up-regulated in breast cancer cells (Figure 
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10). The EENL can more effectively restore the expression of CDH1 than MENL, with higher 
expression of both HDAC1 and HDAC2 and lower expression of Snail. This denotes that EENL 
and MENL may have HDAC inhibitory potential. The level of β-actin remains same in all cases. 
 
Figure 10. Representative images of semi-q-RT-PCR result depicting expression level of 
CDH1, Snail, HDAC-1, HDAC-2 and β-actin after EENL and MENL treatment. 
5.7. Gene Expression Analysis of CDH1and HDAC-1 by quantitative reverse transcription 
PCR (q-RT-PCR) 
 
The real time PCR analysis of mRNA level of CDH1 shows that the CDH1 is up-regulated 
by ten folds in EETL than MENL which is found to be six folds with respect to control (Figure 
11). This supports our finding from semi-q-RT-PCR study. The HDAC-1 is also demonstrated to 
be up-regulated in extract treated cancer cells. From the increase in transcript level of HDAC-1 
in treatment groups, it is apparent that the EENL and MENL have HDAC inhibitory activity. 
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Figure 11.Graphical representation of expression levels of CDH1 & HDAC1 after EENL & 
MENL treatment. 
 
6. CONCLUSION 
From the present investigation, it is apparent that the neem leaf extracts have the anti-
cancer potential. This is revealed from their anti-proliferative, apoptotic and anti-migratory 
activity. Our experiments clearly demonstrate that the EENL exert more anti-cancer effect on 
breast cancer cells than MENL. It is also observed that the EENL can more effectively restore 
the expression of CDH1 with simultaneous increase in transcript level of HDAC-1 and HDAC-2, 
and reduced expression of snail. This indicates the HDAC inhibitory potential of neem leaf 
extract. Further work is needed in order to reveal the HDAC inhibitory activity of neem leaf 
extracts.  
 
 
 
 
 
 
 
 
 
30 
 
7. REFERENCES 
 
1. Sofowora, A., Research on medicinal plants and traditional medicine in Africa. J Altern 
Complement Med, 1996. 2(3): p. 365-72. 
2. Bhargava, K.P., et al., Anti-inflammatory activity of saponins and ot-her natural products. 
Indian J Med Res, 1970. 58(6): p. 724-30. 
3. Pillai, N.R. and G. Santhakumari, Anti-arthritic and anti-inflammatory actions of 
nimbidin. Planta Med, 1981. 43(1): p. 59-63. 
4. Rochanakij, S., et al., Nimbolide, a constituent of Azadirachta indica, inhibits Plasmodium 
falciparum in culture. Southeast Asian J Trop Med Public Health, 1985. 16(1): p. 66-72. 
5. Khalid, S.A., H. Duddeck, and M. Gonzalez-Sierra, Isolation and characterization of an 
antimalarial agent of the neem tree Azadirachta indica. J Nat Prod, 1989. 52(5): p. 922-6. 
6. Jones, I.W., et al., Sexual development of malaria parasites is inhibited in vitro by the 
neem extract azadirachtin, and its semi-synthetic analogues. FEMS Microbiol Lett, 1994. 
120(3): p. 267-73. 
7. van der Nat, J.M., et al., Activity-guided isolation and identification of Azadirachta indica 
bark extract constituents which specifically inhibit chemiluminescence production by 
activated human polymorphonuclear leukocytes. Planta Med, 1991. 57(1): p. 65-8. 
8. Fujiwara, T., et al., Studies on the structure of polysaccharides from the bark of Melia 
azadirachta. Chem Pharm Bull (Tokyo), 1982. 30(11): p. 4025-30. 
9. Patra, S.K., et al., Molecular targets of (-)-epigallocatechin-3-gallate (EGCG): specificity 
and interaction with membrane lipid rafts. J Physiol Pharmacol, 2008. 59 Suppl 9: p. 217-
35. 
10. Parbin, S., et al., Histone deacetylases: a saga of perturbed acetylation homeostasis in 
cancer. J Histochem Cytochem, 2014. 62(1): p. 11-33. 
11. Othman, F., et al., Effect of Neem Leaf Extract (Azadirachta indica) on c-Myc Oncogene 
Expression in 4T1 Breast Cancer Cells of BALB/c Mice. Cell J, 2012. 14(1): p. 53-60. 
12. Jemal, A., et al., Cancer statistics, 2008. CA Cancer J Clin, 2008. 58(2): p. 71-96. 
13. O'Driscoll, L. and M. Clynes, Biomarkers and multiple drug resistance in breast cancer. 
Curr Cancer Drug Targets, 2006. 6(5): p. 365-84. 
31 
 
14. Gonzalez-Angulo, A.M., F. Morales-Vasquez, and G.N. Hortobagyi, Overview of 
resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol, 2007. 
608: p. 1-22. 
15. Longley, D.B. and P.G. Johnston, Molecular mechanisms of drug resistance. J Pathol, 
2005. 205(2): p. 275-92. 
16. Coley, H.M., Mechanisms and strategies to overcome chemotherapy resistance in 
metastatic breast cancer. Cancer Treat Rev, 2008. 34(4): p. 378-90. 
17. Raguz, S. and E. Yague, Resistance to chemotherapy: new treatments and novel insights 
into an old problem. Br J Cancer, 2008. 99(3): p. 387-91. 
18. Lagger, G., et al., Essential function of histone deacetylase 1 in proliferation control and 
CDK inhibitor repression. EMBO J, 2002. 21(11): p. 2672-81. 
19. Osada, H., et al., Heterogeneous transforming growth factor (TGF)-beta unresponsiveness 
and loss of TGF-beta receptor type II expression caused by histone deacetylation in lung 
cancer cell lines. Cancer Res, 2001. 61(22): p. 8331-9. 
20. Yamada, N., et al., MUC2 expression is regulated by histone H3 modification and DNA 
methylation in pancreatic cancer. Int J Cancer, 2006. 119(8): p. 1850-7. 
21. Fritsche, P., et al., HDAC2 mediates therapeutic resistance of pancreatic cancer cells via 
the BH3-only protein NOXA. Gut, 2009. 58(10): p. 1399-409. 
22. Schuler, S., et al., HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells. 
Mol Cancer, 2010. 9: p. 80. 
23. Kim, M.S., et al., Histone deacetylases induce angiogenesis by negative regulation of 
tumor suppressor genes. Nat Med, 2001. 7(4): p. 437-43. 
24. Kim, S.H., K.W. Kim, and J.W. Jeong, Inhibition of hypoxia-induced angiogenesis by 
sodium butyrate, a histone deacetylase inhibitor, through hypoxia-inducible factor-1alpha 
suppression. Oncol Rep, 2007. 17(4): p. 793-7. 
25. Yang, Q.C., et al., Inhibition of hypoxia-induced angiogenesis by trichostatin A via 
suppression of HIF-1a activity in human osteosarcoma. J Exp Clin Cancer Res, 2006. 
25(4): p. 593-9. 
26. Whetstine, J.R., et al., Regulation of tissue-specific and extracellular matrix-related genes 
by a class I histone deacetylase. Mol Cell, 2005. 18(4): p. 483-90. 
32 
 
27. Peinado, H., et al., Snail mediates E-cadherin repression by the recruitment of the 
Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 complex. Mol Cell Biol, 2004. 24(1): p. 
306-19. 
28. von Burstin, J., et al., E-cadherin regulates metastasis of pancreatic cancer in vivo and is 
suppressed by a SNAIL/HDAC1/HDAC2 repressor complex. Gastroenterology, 2009. 
137(1): p. 361-71, 371 e1-5. 
29. Aghdassi, A., et al., Recruitment of histone deacetylases HDAC1 and HDAC2 by the 
transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer. 
Gut, 2012. 61(3): p. 439-48. 
30. Luebeck, E.G. and S.H. Moolgavkar, Multistage carcinogenesis and the incidence of 
colorectal cancer. Proc Natl Acad Sci U S A, 2002. 99(23): p. 15095-100. 
31. Oliveira, P.A., et al., Chemical carcinogenesis. An Acad Bras Cienc, 2007. 79(4): p. 593-
616. 
32. Jemal, A., et al., Cancer statistics, 2010. CA Cancer J Clin, 2010. 60(5): p. 277-300. 
33. Mehta, R.G., et al., Cancer chemoprevention by natural products: how far have we come? 
Pharm Res, 2010. 27(6): p. 950-61. 
34. Desai, A.G., et al., Medicinal plants and cancer chemoprevention. Curr Drug Metab, 2008. 
9(7): p. 581-91. 
35. Soobrattee, M.A., T. Bahorun, and O.I. Aruoma, Chemopreventive actions of 
polyphenolic compounds in cancer. Biofactors, 2006. 27(1-4): p. 19-35. 
36. Krishnaswamy, K., Traditional Indian spices and their health significance. Asia Pac J Clin 
Nutr, 2008. 17 Suppl 1: p. 265-8. 
37. Baade, P.D., D.R. Youlden, and L.J. Krnjacki, International epidemiology of prostate 
cancer: geographical distribution and secular trends. Mol Nutr Food Res, 2009. 53(2): p. 
171-84. 
38. Gangar, S.C., et al., Modulatory effects of Azadirachta indica on benzo(a)pyrene-induced 
forestomach tumorigenesis in mice. World J Gastroenterol, 2006. 12(17): p. 2749-55. 
39. Sritanaudomchai, H., et al., Quinone reductase inducers in Azadirachta indica A. Juss 
flowers, and their mechanisms of action. Asian Pac J Cancer Prev, 2005. 6(3): p. 263-9. 
33 
 
40. Tepsuwan, A., P. Kupradinun, and W.R. Kusamran, Chemopreventive Potential of Neem 
Flowers on Carcinogen-Induced Rat Mammary and Liver Carcinogenesis. Asian Pac J 
Cancer Prev, 2002. 3(3): p. 231-238. 
41. Aruna, K. and V.M. Sivaramakrishnan, Plant products as protective agents against cancer. 
Indian J Exp Biol, 1990. 28(11): p. 1008-11. 
42. Niture, S.K., U.S. Rao, and K.S. Srivenugopal, Chemopreventative strategies targeting the 
MGMT repair protein: augmented expression in human lymphocytes and tumor cells by 
ethanolic and aqueous extracts of several Indian medicinal plants. Int J Oncol, 2006. 
29(5): p. 1269-78. 
43. Priyadarsini, R.V., et al., The neem limonoids azadirachtin and nimbolide inhibit hamster 
cheek pouch carcinogenesis by modulating xenobiotic-metabolizing enzymes, DNA 
damage, antioxidants, invasion and angiogenesis. Free Radic Res, 2009. 43(5): p. 492-
504. 
44. Dasgupta, T., et al., Chemopreventive potential of Azadirachta indica (Neem) leaf extract 
in murine carcinogenesis model systems. J Ethnopharmacol, 2004. 92(1): p. 23-36. 
45. Roy, M.K., et al., Inhibition of colon cancer (HT-29) cell proliferation by a triterpenoid 
isolated from Azadirachta indica is accompanied by cell cycle arrest and up-regulation of 
p21. Planta Med, 2006. 72(10): p. 917-23. 
46. Kumar, S., et al., Anticancer effects of ethanolic neem leaf extract on prostate cancer cell 
line (PC-3). J Ethnopharmacol, 2006. 105(1-2): p. 246-50. 
47. Subapriya, R., R. Kumaraguruparan, and S. Nagini, Expression of PCNA, cytokeratin, 
Bcl-2 and p53 during chemoprevention of hamster buccal pouch carcinogenesis by 
ethanolic neem (Azadirachta indica) leaf extract. Clin Biochem, 2006. 39(11): p. 1080-7. 
48. Harish Kumar, G., et al., Nimbolide a limonoid from Azadirachta indica inhibits 
proliferation and induces apoptosis of human choriocarcinoma (BeWo) cells. Invest New 
Drugs, 2009. 27(3): p. 246-52. 
49. Roy, M.K., et al., Antiproliferative effect on human cancer cell lines after treatment with 
nimbolide extracted from an edible part of the neem tree (Azadirachta indica). Phytother 
Res, 2007. 21(3): p. 245-50. 
34 
 
50. Sharma, C., et al., Ethanolic Neem (Azadirachta indica) Leaf Extract Prevents Growth of 
MCF-7 and HeLa Cells and Potentiates the Therapeutic Index of Cisplatin. J Oncol, 2014. 
2014: p. 321754. 
51. Mahapatra, S., et al., Novel molecular targets of Azadirachta indica associated with 
inhibition of tumor growth in prostate cancer. AAPS J, 2011. 13(3): p. 365-77. 
52. Amati, B., K. Alevizopoulos, and J. Vlach, Myc and the cell cycle. Front Biosci, 1998. 3: 
p. d250-68. 
53. Cory, S., et al., Insights from Bcl-2 and Myc: malignancy involves abrogation of apoptosis 
as well as sustained proliferation. Cancer Res, 1999. 59(7 Suppl): p. 1685s-1692s. 
54. Kim, N.H., S.N. Kim, and Y.K. Kim, Involvement of HDAC1 in E-cadherin expression in 
prostate cancer cells; its implication for cell motility and invasion. Biochem Biophys Res 
Commun, 2011. 404(4): p. 915-21. 
55. Tong, Z.T., et al., EZH2 supports nasopharyngeal carcinoma cell aggressiveness by 
forming a co-repressor complex with HDAC1/HDAC2 and Snail to inhibit E-cadherin. 
Oncogene, 2012. 31(5): p. 583-94. 
56. Hanahan, D. and R.A. Weinberg, The hallmarks of cancer. Cell, 2000. 100(1): p. 57-70. 
57. Peinado, H., F. Portillo, and A. Cano, Transcriptional regulation of cadherins during 
development and carcinogenesis. Int J Dev Biol, 2004. 48(5-6): p. 365-75. 
58. Guarino, M., B. Rubino, and G. Ballabio, The role of epithelial-mesenchymal transition in 
cancer pathology. Pathology, 2007. 39(3): p. 305-18. 
59. Trimboli, A.J., et al., Direct evidence for epithelial-mesenchymal transitions in breast 
cancer. Cancer Res, 2008. 68(3): p. 937-45. 
60. De Wever, O., et al., Molecular and pathological signatures of epithelial-mesenchymal 
transitions at the cancer invasion front. Histochem Cell Biol, 2008. 130(3): p. 481-94. 
61. Sabbah, M., et al., Molecular signature and therapeutic perspective of the epithelial-to-
mesenchymal transitions in epithelial cancers. Drug Resist Updat, 2008. 11(4-5): p. 123-
51. 
62. Lombaerts, M., et al., Infiltrating leukocytes confound the detection of E-cadherin 
promoter methylation in tumors. Biochem Biophys Res Commun, 2004. 319(2): p. 697-
704. 
35 
 
63. Vandewalle, C., et al., SIP1/ZEB2 induces EMT by repressing genes of different epithelial 
cell-cell junctions. Nucleic Acids Res, 2005. 33(20): p. 6566-78. 
64. Cowin, P., T.M. Rowlands, and S.J. Hatsell, Cadherins and catenins in breast cancer. Curr 
Opin Cell Biol, 2005. 17(5): p. 499-508. 
 
 
 
